In an effort to critically define the incidence and clinical characteristics of secondary
responses to cisplatin-based therapy in patients with ovarian cancer previously treated with a …

Purpose The prevalence of BRCA½ mutations in germline DNA from unselected ovarian
cancer patients is 11% to 15.3%. It is important to determine the frequency of somatic BRCA½ …

PURPOSE: To compare the progression-free and overall survival in small-volume residual
ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an …

This updated Fifth Edition provides comprehensive coverage of the biology of gynecologic
cancer, the therapeutic modalities available, and the diagnosis and treatment of site-specific …

Purpose Conflicting results on prognostic factors for advanced epithelial ovarian cancer (EOC)
have been reported because of small sample size and heterogeneity of study population. …

The standard initial management of epithelial ovarian cancer consists of surgical staging,
operative tumour debulking including total abdominal hysterectomy and bilateral salpingo-…

Context.—Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian
cancer cells and is present in the ascitic fluid of patients with ovarian cancer.Objectives.—To …

Purpose: To determine whether continuing paclitaxel for an extended time period in women
with advanced ovarian cancer who had achieved a clinically defined complete response to a …

The last decade witnessed the introduction of exciting new chemotherapeutic agents. Among
these, paclitaxel emerged as one of the most powerful compounds. Paclitaxel promotes the …

PURPOSE: To characterize the clinical features of carboplatin-associated hypersensitivity
reactions. PATIENTS: Patients with gynecologic malignancies treated at the Cleveland Clinic …